• Publications
  • Influence
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
TLDR
Patients with completely resected non-small-cell lung cancer and ERCC1-negative tumors appear to benefit from adjuvant cisplatin-based chemotherapy, whereas patients with ER CC1-positive tumors do not.
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
TLDR
It is emphasised that patients who are considered candidates for a multimodal approach should be included in a prospective trial at a specialised centre, and a three step pre-treatment assessment is proposed.
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.
TLDR
A total of 35 experts met to address several questions on non-small-cell lung cancer in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease.
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.
TLDR
A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, early-stage disease and locally advanced disease.
CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells.
TLDR
It is reported that CD24, a mucin-type glycosylphosphatidylinositol-linked cell surface molecule on human neutrophils, pre B lymphocytes, and many tumors can promote binding to P-selectin, and the role of CD24 is established as a novel ligand for P- selectin on tumor cells.
Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.
TLDR
The data demonstrate that quantification of plasma DNA is an accurate technique amenable to standardization, which might complement current methods for the prediction of patient survival and might be considered for evaluation in large prospective studies.
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.
TLDR
Recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas are focused on.
...
...